Stephen L. Sabba - 10 Jun 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/Stephen L. Sabba
Issuer symbol
LGND
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
4
Filing time
14 Jun 2022, 15:56:14 UTC
Previous filing
08 Jun 2021
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1,004 +4% $0.000000 26,065 10 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 -4,340 -50% $0.000000 4,340 10 Jun 2022 Common Stock 4,340 $79.29 Direct F2
holding LGND Non-Qualified Stock Option (right to buy) 3,269 10 Jun 2022 Common Stock 3,269 $115.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities, as represented in Column 5, include a grant of 1,004 restricted share units approved by the Board of Directors of the Company at the 2022 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
F2 These securities, as represented in Column 5, were acquired by a grant of 4,340 shares approved by the Board of Directors of the Company at the 2022 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.
F3 These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 8, 2021.